Volume 11, Number 10, October 2005

Botulinum Neurotoxin Detection and Differentiation by Mass Spectrometry

John R. Barr,* Hercules Moura,* Anne E. Boyer,* Adrian R. Woolfitt,* Suzanne R. Kalb,* Antonis Pavlopoulos,* Lisa G. McWilliams,† Jurgen G. Schmidt,‡ Rodolfo A. Martinez,‡ and David L. Ashley*
*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Battelle Memorial Institute, Atlanta, Georgia, USA; and ‡Los Alamos National Laboratory, Los Alamos, New Mexico, USA

Figure 2. Substrate peptide sequences, the botulinum neurotoxin (BoNT) serotype predicted cleavage product sequences, and masses of the substrate and product peptides. Peptides for BoNT-A and -E were derived from the human SNAP (synaptosomal-associated protein)-25 protein. The substrate peptide for BoNT A, 187-SNKTRIDEANQRATKML-203, was modified to biotin(ε)-KG(K189->R and K201->R)GGK-(ε)Biotin. The BoNT-E substrate sequence was also from human SNAP-25 (156–186). Substrate peptides for BoNT-B and -F are from human synaptobrevin 2; the BoNT-B substrate (3) is from 59–93 in the sequence and the BoNT-F substrate is from 35–74.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed August 24, 2005

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention